A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania (Q34649372)

3 August 2017

title

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania (English)

1 reference

3 August 2017

10

1 reference

3 August 2017

Ashley I Bush

3

0 references

Gin Malhi

series ordinal

5

object named as

Gin S Malhi

1 reference

3 August 2017

2

Olivia M Dean

1 reference

3 August 2017

6

Kristy Kohlmann

1 reference

3 August 2017

8

Ian Schapkaitz

1 reference

3 August 2017

9

Murray Anderson-Hunt

1 reference

3 August 2017

4

David L Copolov

1 reference

3 August 2017

7

Susan Jeavons

1 reference

3 August 2017

author name string

Pedro Vieira da Silva Magalhães

series ordinal

1

1 reference

3 August 2017

publication date

14 March 2013

1 reference

Australian and New Zealand Journal of Psychiatry

3 August 2017

published in

1 reference

3 August 2017

volume

47

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

564-568

1 reference

Serum S100B and antioxidant enzymes in bipolar patients.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

The Bipolar Depression Rating Scale (BDRS): its development, validation and utility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

The promise of N-acetylcysteine in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Scale matters: the need for a Bipolar Depression Rating Scale (BDRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Glutathione: a novel treatment target in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

The empirical redefinition of the psychometric criteria for remission in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Translating the Rosetta Stone of N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Mediators of allostasis and systemic toxicity in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Peripheral biomarkers and illness activity in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

New therapeutic targets for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-acetylcysteine for major depressive episodes in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

N-Acetylcysteine reverses cocaine-induced metaplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

The specificity of platelet glutamate receptor supersensitivity in psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

Effect of Chronic N-Acetyl Cysteine Administration on Oxidative Status in the Presence and Absence of Induced Oxidative Stress in Rat Striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867413481631

21 January 2018

Identifiers

DOI

10.1177/0004867413481631

1 reference

3 August 2017

1 reference